Trials of a personalised vaccine against the debilitating disease multiple sclerosis are due to go ahead following approval from regulators. If the trial is a success, patients would receive four injections a year to slow or even halt the progress of the disease. Existing drugs that are able to reduce symptoms in some patients must be taken daily or weekly.
The vaccine targets a common form of multiple sclerosis called relapsing and remitting MS, which affects 70% of patients, most of whom are young and in the early stages of the disease. It differs from other treatments by using a patient's own cells to make the body fight the condition.,00.html